Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Baker Brothers Reports Stakes in InterMune and Repros Therapeutics

Page 1 of 2

Baker Brothers, a healthcare focused hedge fund managed by Julian and Felix Baker, has recently filed with the SEC to disclose significant percentage stakes in two development stage biotechnology companies. The fund now owns 2.6 million shares of InterMune, Inc. (NASDAQ:ITMN), giving it 3.3% of the outstanding shares of the stock, and 1.5 million shares- nearly 9%- of Repros Therapeutics Inc (NASDAQ:RPRX).

InterMune Inc (NASDAQ:ITMN)

InterMune’s focus is on treatments and potential treatments for idiopathic pulmonary fibrosis; the stock’s market cap is only about $650 million, but 1.7 million shares are traded on average per day. Repros’s products in development are aimed at disorders in the hormonal and reproductive systems. It too is a smaller-cap stock, with a market capitalization of about $210 million, but with about 470,000 shares traded per day and a current stock price of over $12 we would say that as with InterMune there is plenty of liquidity available for most investors’ purposes. See more of Baker Brother’s stock picks; the fund’s top healthcare stocks include Pharmacyclics, Inc. (NASDAQ:PCYC), Seattle Genetics, Inc. (NASDAQ:SGEN), and Synageva BioPharma Corp (NASDAQ:GEVA) where we have found some insider buying activity recently (read more about insider purchases at Synageva).

Repros is more or less purely in the development stage of its business; the company was earning essentially no revenue in the first three quarters of 2012. Wall Street analysts expect that it will at least remain unprofitable for 2013, with losses per share for the year expected to come in at $1.28. However, the stock has more than doubled in the last year on positive development news (though a delay in study results announced in January has sent the stock down over 20% year to date). The most recent data shows that 19% of the outstanding shares are held short.

InterMune is generating a small amount of revenue, but it too is still unprofitable and analyst expectations are for negative $3.02 in EPS for 2013. It is an even more popular short candidate than Repros, with almost 30% of shares held short. This company’s stock price has fallen 38% in the last year as news has not been particularly good. While InterMune does have a large cash hoard on its balance sheet (at about $350 million) it also has about $240 million in debt. So while a significant share of its market cap is cash, the company is still priced at an enterprise value of over $500 million.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!